NCT03927170View on ClinicalTrials.gov

Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

September 11, 2019

Study Completion Date

October 23, 2019

Conditions
Healthy
Interventions
COMBINATION_PRODUCT

Janumet XR tablet 100/1000 mg

To administrate the Janumet XR tablet

COMBINATION_PRODUCT

GLH1SM tablet 100/1000 mg

To administrate the GLH1SM tablet

Trial Locations (1)

54907

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

GL Pharm Tech Corporation

INDUSTRY